What is normal testosterone level for my age?

Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study

Objective: There is little consensus on what androgen levels are ‘normal’ for healthy, ageing men. Using data from the Massachusetts Male Ageing Study (MMAS), we estimated age-specific, normal androgen levels for men aged 40-79 years while accounting for health status and behavioural factors known to influence hormone levels.

Design: Prospective, observational study.

Patients: Community-based random sample of men aged 40-79 years: n = 1677 men studied at T1 (1987-1989), n = 1031 at T2 (1995-1997) and n = 631 at T3 (2002-2004), for a total of 3339 observations. The average number of years between the T1 and T2 interviews was 8.8 (range 7.1-10.4 years) and 6.4 (range 5.6-7.9 years) between T2 and T3.

Measurements: Serum total testosterone (T) and sex hormone-binding globulin (SHBG) were measured on nonfasting blood samples collected within 4 h of subject’s awakening. Free and bio-available T were calculated from T and SHBG using the Sodergard equation. Trained interviewers administered an in-home questionnaire of health, medication and lifestyle. Participants were considered apparently healthy if all of the following were met: (i) absence of self-reported chronic disease (diabetes, heart disease, high blood pressure, cancer, ulcer); (ii) not on prescription medication believed to affect hormone levels; (iii) body mass index (BMI) not exceeding 29 kg/m2; (iv) alcohol consumption less than or equal to six drinks/day; and (v) nonsmoking.

Results: Chronic disease and high BMI significantly decreased whereas smoking tended to increase total, free and bio-available T concentrations. Apparently healthy men had significantly higher median hormone concentrations at most time points than did not apparently healthy men. Due to the opposite effects of smoking and the other components of the definition, apparently healthy men were compared to nonsmoking, apparently unhealthy men. The former group had significantly higher androgen levels (Wilcoxon rank-sum P-values ranged from 0.01 to 0.0001) for all hormones at all interviews. Ninety-five percent of apparently healthy men in their 40s, 50s, 60s and 70s would be expected to have total T in the range (2.5-97.5th percentile): 8.7-31.7, 7.5-30.4, 6.8-29.8 and 5.4-28.4 nm (251-914, 216-876, 196-859, 156-818 ng/dl), respectively.

Conclusions: Age, health and lifestyle factors impact androgen levels and should be accounted for in calculations of normal reference ranges. We propose the following age-specific thresholds, below which a man is considered to have an abnormally low total T: 8.7, 7.5, 6.8 and 5.4 nm (251, 216, 196 and 156 ng/dl) for men in their 40s, 50s, 60s and 70s, respectively. These cutoffs correspond to the 2.5th percentile in our data; thus, approximately 2.5% of men aged 40-79 years would have abnormally low T levels based on hormone levels alone.

Comment in

Barrett-Connor E. Barrett-Connor E. Clin Endocrinol (Oxf). 2005 Mar;62(3):263-4. doi: 10.1111/j.1365-2265.2005.02232.x. Clin Endocrinol (Oxf). 2005. PMID: 15730406 No abstract available.

Similar articles

de Ronde W, van der Schouw YT, Pierik FH, Pols HA, Muller M, Grobbee DE, Gooren LJ, Weber RF, de Jong FH. de Ronde W, et al. Clin Endocrinol (Oxf). 2005 Apr;62(4):498-503. doi: 10.1111/j.1365-2265.2005.02252.x. Clin Endocrinol (Oxf). 2005. PMID: 15807883

Li JY, Li XY, Li M, Zhang GK, Ma FL, Liu ZM, Zhang NY, Meng P. Li JY, et al. Aging Male. 2005 Sep-Dec;8(3-4):203-6. doi: 10.1080/13685530500356010. Aging Male. 2005. PMID: 16390747

Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SA, Jamrozik K, Hankey GJ, Flicker L. Yeap BB, et al. Clin Endocrinol (Oxf). 2009 Mar;70(3):455-63. doi: 10.1111/j.1365-2265.2008.03372.x. Epub 2008 Aug 7. Clin Endocrinol (Oxf). 2009. PMID: 18691270

Magoha GA. Magoha GA. East Afr Med J. 1997 Oct;74(10):642-4. East Afr Med J. 1997. PMID: 9529746 Review.

Swerdloff RS, Wang C. Swerdloff RS, et al. Best Pract Res Clin Endocrinol Metab. 2004 Sep;18(3):349-62. doi: 10.1016/j.beem.2004.03.011. Best Pract Res Clin Endocrinol Metab. 2004. PMID: 15261842 Review.

Cited by

Wu FC, Huhtaniemi IT. Wu FC, et al. Rev Endocr Metab Disord. 2022 Dec;23(6):1105-1107. doi: 10.1007/s11154-022-09761-6. Epub 2022 Nov 2. Rev Endocr Metab Disord. 2022. PMID: 36322297 Free PMC article. Review. No abstract available.

Kadyrov M, Whiley L, Brown B, Erickson KI, Holmes E. Kadyrov M, et al. Metabolites. 2022 Aug 31;12(9):822. doi: 10.3390/metabo12090822. Metabolites. 2022. PMID: 36144226 Free PMC article. Review.

Dhindsa S, Champion C, Deol E, Lui M, Campbell R, Newman J, Yeggalam A, Nadella S, Ahir V, Shrestha E, Kannampallil T, Diwan A. Dhindsa S, et al. JAMA Netw Open. 2022 Sep 1;5(9):e2229747. doi: 10.1001/jamanetworkopen.2022.29747. JAMA Netw Open. 2022. PMID: 36053534 Free PMC article.

Isidori AM, Aversa A, Calogero A, Ferlin A, Francavilla S, Lanfranco F, Pivonello R, Rochira V, Corona G, Maggi M. Isidori AM, et al. J Endocrinol Invest. 2022 Dec;45(12):2385-2403. doi: 10.1007/s40618-022-01859-7. Epub 2022 Aug 26. J Endocrinol Invest. 2022. PMID: 36018454 Free PMC article.

Corona G, Maggi M. Corona G, et al. Rev Endocr Metab Disord. 2022 Dec;23(6):1159-1172. doi: 10.1007/s11154-022-09748-3. Epub 2022 Aug 23. Rev Endocr Metab Disord. 2022. PMID: 35999483 Free PMC article. Review.

Cheap Canadian Pharma LLC. 775 Cambie St, Vancouver, BC, Canada. All Rights Reserved.